News / Blog
Delivery and Holidays in September
Catalog
Ebastine OD tablets 10 mg for allergy treatment
Product Code :
Availability : 12
USD 105.00
General information on Japanese Ebastine OD tablets 10 mg for allergy treatment
Package details: 100 tablets
Manufacturer: Nipro Corporation, Japan
Active ingredient: ebastine (chemical formula C32H39NO2)
Medical effect: Ebastine tablets are effective for treatment of the following diseases and conditions:
- hives,
- eczema or dermatitis,
- prurigo,
- cutaneous pruritus,
- allergic rhinitis.
Contraindications and precautions: do not use for pregnant and breastfeeding women.
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
As this medicine may cause sleepiness, be careful when operating in potentially hazardous activities such as driving a car.
Dosage and administration of Ebastine OD tablets 10 mg from Japan for allergy treatment
For adults: Take 0.5-1 tablet (5-10 mg of the active ingredient) at a time once a day. The consulting doctor may increase or decrease the dosage according to age and symptoms.
The medicine can be taken in 2 ways. Either take it with water. Or take it without water, crushing the medicine with the tongue and subsequently swallowing it with saliva.
How effective are Ebastine OD tablets 10 mg from Japan for allergy treatment?
Ebastine is a fast-acting second-generation H1 receptor antagonist. It is effective for the treatment of both seasonal and perennial allergic rhinitis, hives, eczema or dermatitis, prurigo and cutaneous pruritus.
Who should take Ebastine OD tablets 10 mg from Japan?
Ebastine does not penetrate the blood–brain barrier and is considered well-tolerated and generally safe. Studies showed that it has rapid onset, provides efficacy throughout the 24 hours dosing interval with once-daily administration and clinical benefit is seen from the first day of treatment (J. Sastre. “Ebastine in allergic rhinitis and chronic idiopathic urticaria”. Allergy, 2008, 63, December, Suppl. 89: 1-20).